CYP3A4 and hepatocellular carcinoma: Clinically, HCC patients with higher levels of CYP3A4, HNF4α and albumin showed better 5‐year OS and PFS compared with those patients exhibiting lower levels of these differentiation markers (Figure 1C,D), supporting the potential of infigratinib‐mediated differentiation therapy in HCC.